Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity
Alisa B. Lee‐Sherick, Kristen M. Jacobsen, Curtis J. Henry, et al.
JCI Insight (2018) Vol. 3, Iss. 21
Open Access | Times Cited: 67

Showing 26-50 of 67 citing articles:

Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma
Naita M. Wirsik, Mingyi Chen, Liping He, et al.
Cancer Medicine (2024) Vol. 13, Iss. 7
Open Access | Times Cited: 3
MERTK inhibition selectively activates a DC – T-cell axis to provide anti-leukemia immunity
Justus M. Huelse, Swati S. Bhasin, Kristen M. Jacobsen, et al.
Leukemia (2024) Vol. 38, Iss. 12, pp. 2685-2698
Closed Access | Times Cited: 3
Navigating TAM receptor dynamics in tumour immunotherapy
Jihao Yang, Guanmin Chen, Rui Wang, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 5
Open Access
The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients
Arjun Khunger, Julie Rytlewski, Paul Fields, et al.
OncoImmunology (2019) Vol. 8, Iss. 11, pp. e1652538-e1652538
Open Access | Times Cited: 26
Optimization of an Imidazo[1,2-a]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy
William McCoull, Scott Boyd, Martin R. Brown, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 18, pp. 13524-13539
Closed Access | Times Cited: 23
MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
Chao‐Ju Chen, Yu‐Peng Liu
Pharmaceuticals (2021) Vol. 14, Iss. 2, pp. 130-130
Open Access | Times Cited: 22
Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia
Silvia Jiménez‐Morales, Iván Sammir Aranda-Uribe, Carlos Jhovani Pérez-Amado, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 21
The role of macrophage TAM receptor family in the acute‐to‐chronic progression of liver disease: From friend to foe?
Haitao Huang, Jingyu Jiang, Ruihan Chen, et al.
Liver International (2022) Vol. 42, Iss. 12, pp. 2620-2631
Closed Access | Times Cited: 16
Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment
Jane Koo, Masanori Hayashi, Michael R. Verneris, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 21
TAM kinase inhibition and immune checkpoint blockade– a winning combination in cancer treatment?
Pavlos Msaouel, Giannicola Genovese, Jianjun Gao, et al.
Expert Opinion on Therapeutic Targets (2020) Vol. 25, Iss. 2, pp. 141-151
Closed Access | Times Cited: 21
MerTK Induces Dysfunctional Dendritic Cells by Metabolic Reprogramming
Eden Y. Zewdie, George M. Edwards, Debra M. Hunter, et al.
Cancer Immunology Research (2024) Vol. 12, Iss. 9, pp. 1268-1285
Closed Access | Times Cited: 2
MERTK Inhibition as a Targeted Novel Cancer Therapy
K.M. Tanim, Alisha Holtzhausen, Aashis Thapa, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7660-7660
Open Access | Times Cited: 2
Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with In Vivo Target Engagement
Robin R. Frey, Navendu Jana, Jacob V. Gorman, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
<p>Protein kinase C-iota-mediated glycolysis promotes non-small-cell lung cancer progression</p>
Liu Liu, Bei Lei, Lihua Wang, et al.
OncoTargets and Therapy (2019) Vol. Volume 12, pp. 5835-5848
Open Access | Times Cited: 19
Immunological role of TAM receptors in the cancer microenvironment
Varsha Gadiyar, Gopi Patel, Viralkumar Davra
International review of cell and molecular biology (2020), pp. 57-79
Closed Access | Times Cited: 18
Efferocytosis drives myeloid NLRP3 dependent inflammasome signaling secretion of IL-1β to promote tumor growth
Cara Lang, Sohini Roy, Yu Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 10
A Real-Time Image-Based Efferocytosis Assay for the Discovery of Functionally Inhibitory Anti-MerTK Antibodies
Daniel D. Bravo, Yongchang Shi, Allison Sheu, et al.
The Journal of Immunology (2023) Vol. 210, Iss. 8, pp. 1166-1176
Open Access | Times Cited: 6
Immuno-oncology: are TAM receptors in glioblastoma friends or foes?
Yunxiang Zhou, Yali Wang, Hailong Chen, et al.
Cell Communication and Signaling (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 14
Immunological responses in SARS-CoV-2 and HIV co-infection versus SARS-CoV-2 mono-infection: case report of the interplay between SARS-CoV-2 and HIV
Shima Shahbaz, Wendy Sligl, Mohammed Osman, et al.
Allergy Asthma and Clinical Immunology (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 5
TAM receptors: A phosphatidylserine receptor family and its implications in viral infections
Sounak Ghosh Roy
International review of cell and molecular biology (2020), pp. 81-122
Closed Access | Times Cited: 14
UNC5293, a potent, orally available and highly MERTK-selective inhibitor
Hongchao Zheng, Jichen Zhao, Bing Li, et al.
European Journal of Medicinal Chemistry (2021) Vol. 220, pp. 113534-113534
Closed Access | Times Cited: 11
Tyro3, Axl, Mertk receptor-mediated efferocytosis and immune regulation in the tumor environment
Liwen Zhou, Glenn K. Matsushima
International review of cell and molecular biology (2021), pp. 165-210
Closed Access | Times Cited: 11
Design, Synthesis, and Biological Evaluation of 2-Substituted Aniline Pyrimidine Derivatives as Potent Dual Mer/c-Met Inhibitors
Daowei Huang, Huiling Chen, Jixia Yang, et al.
Molecules (2024) Vol. 29, Iss. 2, pp. 475-475
Open Access | Times Cited: 1
In the Eyes of the Beholder—New Mertk Knockout Mouse and Re-Evaluation of Phagocytosis versus Anti-Inflammatory Functions of MERTK
Sourav Ghosh, Silvia C. Finnemann, Douglas Vollrath, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5299-5299
Open Access | Times Cited: 1
Dynamics of clonal hematopoiesis and risk of hematologic malignancy
Christopher Maximilian Arends, Siddhartha Jaiswal
International Journal of Hematology (2024)
Closed Access | Times Cited: 1

Scroll to top